MAIA Biotechnology 

$1.3050
43
-$0.03-1.88% 16:35 Today

Statistics

Day High
1.35
Day Low
1.3
52W High
3.19
52W Low
0.87
Volume
131,223
Avg. Volume
531,357
Mkt Cap
79.39M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.32
-0.26
-0.19
-0.13
Expected EPS
-0.13
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-22.4MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MAIA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a leading pharmaceutical company that competes with MAIA in the oncology sector, particularly in developing cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb is involved in the discovery, development, and delivery of cancer therapies, directly competing with MAIA's focus on innovative oncology treatments.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a broad portfolio of oncology drugs and invests heavily in cancer research, making it a competitor in the cancer treatment market alongside MAIA.
Novartis
NVS
Mkt Cap292.35B
Novartis AG is a global healthcare company that competes with MAIA in developing advanced therapies for various cancers.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is known for its strong presence in the oncology and hematology market, competing with MAIA in cancer treatment research and development.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. focuses on human therapeutics, including oncology/hematology, which puts it in direct competition with MAIA Biotechnology's cancer treatment innovations.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG operates in the pharmaceuticals and diagnostics sectors, with a significant focus on oncology, making it a competitor in cancer treatment advancements.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong pipeline in oncology, competing with MAIA in developing new cancer therapies.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for various diseases, including cancer, competing with MAIA in the oncology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions, including cancer, competing with MAIA in the biotechnology and oncology fields.

About

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Show more...
CEO
Vlad Vitoc
Employees
13
Country
United States
ISIN
US5526411021

Listings

0 Comments

Share your thoughts

FAQ

What is MAIA Biotechnology stock price today?
The current price of MAIA is $1.31 USD — it has decreased by -1.88% in the past 24 hours. Watch MAIA Biotechnology stock price performance more closely on the chart.
What is MAIA Biotechnology stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange MAIA Biotechnology stocks are traded under the ticker MAIA.
Is MAIA Biotechnology stock price growing?
MAIA stock has fallen by -1.5% compared to the previous week, the month change is a -3.68% fall, over the last year MAIA Biotechnology has showed a -12.08% decrease.
What is MAIA Biotechnology market cap?
Today MAIA Biotechnology has the market capitalization of 79.39M
When is the next MAIA Biotechnology earnings date?
MAIA Biotechnology is going to release the next earnings report on November 10, 2026.
What were MAIA Biotechnology earnings last quarter?
MAIA earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.13 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MAIA Biotechnology revenue for the last year?
MAIA Biotechnology revenue for the last year amounts to 0 USD.
What is MAIA Biotechnology net income for the last year?
MAIA net income for the last year is -22.4M USD.
How many employees does MAIA Biotechnology have?
As of September 04, 2026, the company has 13 employees.
In which sector is MAIA Biotechnology located?
MAIA Biotechnology operates in the Health & Wellness sector.
When did MAIA Biotechnology complete a stock split?
MAIA Biotechnology has not had any recent stock splits.
Where is MAIA Biotechnology headquartered?
MAIA Biotechnology is headquartered in CHICAGO, United States.